HyTest Ltd., Turku, Finland.
Clin Chim Acta. 2011 May 12;412(11-12):850-60. doi: 10.1016/j.cca.2011.03.006. Epub 2011 Mar 21.
B-type Natriuretic Peptide (BNP) is a circulating hormone primarily produced by the myocardium in response to volume overload and increased filling pressure. BNP acts to increase natriuresis and to decrease cardiac load and blood pressure. The appearance of active BNP hormone in the bloodstream is preceded by the proteolytic cleavage of its precursor, proBNP. The products of proBNP processing, BNP and the N-terminal fragment of proBNP (NT-proBNP), have been extensively shown to be powerful biomarkers of heart failure (HF) and risk assessments for cardiovascular complications. In contrast to the clinical utility of proBNP-derived peptides, knowledge of posttranslational proBNP maturation and molecular aspects of its processing are far from being completely comprehended. A clear understanding of proBNP processing mechanisms in normal and diseased states appears to be required to improve our understanding of HF development and the clinical significance of both proBNP and proBNP-derived peptides. The aim of the present review is to summarize the available data in the field of human proBNP maturation and processing and to discuss potential clinical implications.
B 型利钠肽(BNP)是一种循环激素,主要由心肌产生,以响应容量过载和充盈压升高。BNP 可增加钠排泄,降低心脏负荷和血压。活性 BNP 激素在血液中的出现先于其前体,即前 BNP 的蛋白水解切割。前 BNP 加工的产物,BNP 和前 BNP 的 N 端片段(NT-proBNP),已被广泛证明是心力衰竭(HF)的强大生物标志物和心血管并发症风险评估的指标。与前 BNP 衍生肽的临床应用相比,对前 BNP 成熟的翻译后修饰和分子加工方面的了解还远远不够。似乎需要清楚地了解正常和疾病状态下的前 BNP 加工机制,以提高我们对 HF 发展以及前 BNP 和前 BNP 衍生肽的临床意义的理解。本综述的目的是总结人类前 BNP 成熟和加工领域的现有数据,并讨论潜在的临床意义。